I don't think that Fidelity matter too much whether they sell more or stay put.
$8m half year loss doesn't scream out Buy, but things will change very quickly from here with costs cut and revenue rising. The ongoing roll out of Astra Zeneca alone has been completely ignored by the market. That relationship is worth far more than the market cap in its own right.
